145 related articles for article (PubMed ID: 3015014)
1. Characterization of a varicella-zoster virus variant with altered thymidine kinase activity.
Shigeta S; Mori S; Yokota T; Konno K; De Clercq E
Antimicrob Agents Chemother; 1986 Jun; 29(6):1053-8. PubMed ID: 3015014
[TBL] [Abstract][Full Text] [Related]
2. Incorporation of (E)-5-(2-iodovinyl)-2'-deoxyuridine into deoxyribonucleic acids of varicella-zoster virus (TK+ and TK- strains)-infected cells.
Yokota T; Konno K; Shigeta S; Verbruggen A; De Clercq E
Mol Pharmacol; 1987 May; 31(5):493-9. PubMed ID: 3033468
[TBL] [Abstract][Full Text] [Related]
3. Differential phosphorylation of (E)-5-(2-bromovinyl)-2'-deoxyuridine monophosphate by thymidylate kinases from herpes simplex viruses types 1 and 2 and varicella zoster virus.
Fyfe JA
Mol Pharmacol; 1982 Mar; 21(2):432-7. PubMed ID: 6285172
[TBL] [Abstract][Full Text] [Related]
4. Thymidylate synthase is the principal target enzyme for the cytostatic activity of (E)-5-(2-bromovinyl)-2'-deoxyuridine against murine mammary carcinoma (FM3A) cells transformed with the herpes simplex virus type 1 or type 2 thymidine kinase gene.
Balzarini J; De Clercq E; Verbruggen A; Ayusawa D; Shimizu K; Seno T
Mol Pharmacol; 1987 Sep; 32(3):410-6. PubMed ID: 2823092
[TBL] [Abstract][Full Text] [Related]
5. Deoxypyrimidine nucleoside metabolism in varicella-zoster virus-infected cells.
Hackstadt T; Mallavia LP
J Virol; 1978 Feb; 25(2):510-7. PubMed ID: 24124
[TBL] [Abstract][Full Text] [Related]
6. Specific recognition of the bicyclic pyrimidine nucleoside analogs, a new class of highly potent and selective inhibitors of varicella-zoster virus (VZV), by the VZV-encoded thymidine kinase.
Sienaert R; Naesens L; Brancale A; De Clercq E; McGuigan C; Balzarini J
Mol Pharmacol; 2002 Feb; 61(2):249-54. PubMed ID: 11809847
[TBL] [Abstract][Full Text] [Related]
7. Susceptibility of protein kinase (ORF47)-deficient varicella-zoster virus strains to anti-herpesvirus nucleosides.
Suzutani T; Ogasawara M; Shibaki T; Azuma M
Antiviral Res; 2000 Jan; 45(1):79-82. PubMed ID: 10774592
[TBL] [Abstract][Full Text] [Related]
8. Selective radiosensitization of drug-resistant MutS homologue-2 (MSH2) mismatch repair-deficient cells by halogenated thymidine (dThd) analogues: Msh2 mediates dThd analogue DNA levels and the differential cytotoxicity and cell cycle effects of the dThd analogues and 6-thioguanine.
Berry SE; Davis TW; Schupp JE; Hwang HS; de Wind N; Kinsella TJ
Cancer Res; 2000 Oct; 60(20):5773-80. PubMed ID: 11059773
[TBL] [Abstract][Full Text] [Related]
9. Analysis of mutations in the thymidine kinase gene of varicella zoster virus associated with resistance to 5-iodo-2'-deoxyuridine and 5-bromo-2'-deoxyuridine.
Kodama E; Mori S; Shigeta S
Antiviral Res; 1995 May; 27(1-2):165-70. PubMed ID: 7486953
[TBL] [Abstract][Full Text] [Related]
10. In vitro susceptibility of varicella-zoster virus to E-5-(2-bromovinyl)-2'-deoxyuridine and related compounds.
De Clercq E; Descamps J; Ogata M; Shigeta S
Antimicrob Agents Chemother; 1982 Jan; 21(1):33-8. PubMed ID: 6282207
[TBL] [Abstract][Full Text] [Related]
11. Clinical isolate of herpes simplex virus type 2 that induces a thymidine kinase with altered substrate specificity.
Ellis MN; Keller PM; Fyfe JA; Martin JL; Rooney JF; Straus SE; Lehrman SN; Barry DW
Antimicrob Agents Chemother; 1987 Jul; 31(7):1117-25. PubMed ID: 2821890
[TBL] [Abstract][Full Text] [Related]
12. Differential metabolism of (E)-5-(2-iodovinyl)-2'-deoxyuridine (IVDU) by equine herpesvirus type 1- and herpes simplex virus-infected cells.
Kit S; Ichimura H; De Clercq E
Antiviral Res; 1987 Aug; 8(1):41-51. PubMed ID: 2825591
[TBL] [Abstract][Full Text] [Related]
13. Differential affinities of 5-(2-halogenovinyl)-2'-deoxyuridines for deoxythymidine kinases of various origins.
Cheng YC; Dutschman G; De Clercq E; Jones AS; Rahim SG; Verhelst G; Walker RT
Mol Pharmacol; 1981 Jul; 20(1):230-3. PubMed ID: 6270535
[No Abstract] [Full Text] [Related]
14. Specific phosphorylation of E-5-(2-iodovinyl)-2'-deoxyuridine by herpes simplex virus-infected cells.
Descamps J; De Clercq E
J Biol Chem; 1981 Jun; 256(12):5973-6. PubMed ID: 6263899
[TBL] [Abstract][Full Text] [Related]
15. Comparative inhibition of DNA polymerases from varicella zoster virus (TK+ and TK-) strains by (E)-5-(2-bromovinyl)-2'-deoxyuridine 5'-triphosphate.
Yokota T; Konno K; Shigeta S; De Clercq E
Mol Pharmacol; 1984 Sep; 26(2):376-80. PubMed ID: 6090888
[TBL] [Abstract][Full Text] [Related]
16. Antiviral activity of oxetanocins against varicella-zoster virus.
Sakuma T; Saijo M; Suzutani T; Yoshida I; Saito S; Kitagawa M; Hasegawa S; Azuma M
Antimicrob Agents Chemother; 1991 Jul; 35(7):1512-4. PubMed ID: 1656865
[TBL] [Abstract][Full Text] [Related]
17. Mutant varicella-zoster virus thymidine kinase: correlation of clinical resistance and enzyme impairment.
Roberts GB; Fyfe JA; Gaillard RK; Short SA
J Virol; 1991 Dec; 65(12):6407-13. PubMed ID: 1658351
[TBL] [Abstract][Full Text] [Related]
18. Comparative efficacy of antiherpes drugs against various strains of varicella-zoster virus.
Shigeta S; Yokota T; Iwabuchi T; Baba M; Konno K; Ogata M; De Clercq E
J Infect Dis; 1983 Mar; 147(3):576-84. PubMed ID: 6300257
[TBL] [Abstract][Full Text] [Related]
19. Mechanism of selective inhibition of varicella zoster virus replication by 1-beta-D-arabinofuranosyl-E-5-(2-bromovinyl)uracil.
Yokota T; Konno K; Mori S; Shigeta S; Kumagai M; Watanabe Y; Machida H
Mol Pharmacol; 1989 Aug; 36(2):312-6. PubMed ID: 2549386
[TBL] [Abstract][Full Text] [Related]
20. Structure-activity relationship of the affinity of 5-substituted uracil nucleoside analogues for varicella-zoster virus thymidine kinase and their activity against varicella-zoster virus.
Ashida N; Watanabe Y; Miura S; Kano F; Sakata S; Yamaguchi T; Suzutani T; Machida H
Antiviral Res; 1997 Aug; 35(3):167-75. PubMed ID: 9298756
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
